MA22842A1 - Procede de preparation de compositions de vaccin. - Google Patents

Procede de preparation de compositions de vaccin.

Info

Publication number
MA22842A1
MA22842A1 MA23137A MA23137A MA22842A1 MA 22842 A1 MA22842 A1 MA 22842A1 MA 23137 A MA23137 A MA 23137A MA 23137 A MA23137 A MA 23137A MA 22842 A1 MA22842 A1 MA 22842A1
Authority
MA
Morocco
Prior art keywords
preparation
vaccine compositions
vaccine
compositions
Prior art date
Application number
MA23137A
Other languages
English (en)
Inventor
Hauser Pierre
Voet Pierre
Marie Josephe Claude Nathalie
Thiriart Clothide
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA22842(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of MA22842A1 publication Critical patent/MA22842A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA23137A 1992-03-27 1993-03-23 Procede de preparation de compositions de vaccin. MA22842A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine

Publications (1)

Publication Number Publication Date
MA22842A1 true MA22842A1 (fr) 1993-10-01

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23137A MA22842A1 (fr) 1992-03-27 1993-03-23 Procede de preparation de compositions de vaccin.

Country Status (28)

Country Link
EP (1) EP0633784B2 (fr)
JP (1) JP3470719B2 (fr)
KR (1) KR100270134B1 (fr)
CN (1) CN1072963C (fr)
AP (1) AP570A (fr)
AT (1) ATE146678T1 (fr)
AU (4) AU3751693A (fr)
CA (1) CA2132833C (fr)
CZ (1) CZ283424B6 (fr)
DE (1) DE69306940T3 (fr)
DK (1) DK0633784T4 (fr)
ES (1) ES2098029T5 (fr)
FI (1) FI110843B (fr)
GR (1) GR3022174T3 (fr)
HK (1) HK1003218A1 (fr)
HU (1) HU221253B1 (fr)
IL (1) IL105161A (fr)
MA (1) MA22842A1 (fr)
MY (1) MY111880A (fr)
NO (1) NO309458B1 (fr)
NZ (1) NZ249868A (fr)
RU (1) RU2121849C1 (fr)
SA (1) SA93130573B1 (fr)
SG (1) SG48375A1 (fr)
SI (1) SI9300149B (fr)
SK (1) SK280160B6 (fr)
UA (1) UA44688C2 (fr)
WO (1) WO1993019780A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
RU2116086C1 (ru) * 1997-08-19 1998-07-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Способ вакцинации против вирусного гепатита b
DE69933200T2 (de) * 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
RU2135209C1 (ru) * 1998-07-17 1999-08-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Фармацевтическая композиция для иммунопрофилактики вирусного гепатита b
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
AU750587B2 (en) * 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP2298340B1 (fr) 2004-09-22 2014-04-16 GlaxoSmithKline Biologicals S.A. Composition immunogène pour la vaccination contre des staphylocoques
PE20061428A1 (es) 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
NZ567979A (en) 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
WO2007052155A2 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BR122019013216B8 (pt) 2006-01-27 2021-07-27 Seqirus Uk Ltd ensaio imunológico para análise de uma vacina contra influenza
WO2007109813A1 (fr) 2006-03-23 2007-09-27 Novartis Ag Composés d'imidazoquinoxaline utilisés en tant qu'immunomodulateurs
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP3456348B1 (fr) 2006-09-11 2025-03-26 Seqirus UK Limited Fabrication de vaccins contre le virus de la grippe sans utiliser d' oeufs
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
US8685654B2 (en) 2007-12-24 2014-04-01 Novartis Ag Assays for adsorbed influenza vaccines
WO2010099580A1 (fr) * 2009-03-05 2010-09-10 Jenny Colleen Mccloskey Traitement d'une infection
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CN103282375B (zh) 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计
AU2012204955B2 (en) 2011-01-06 2016-10-06 Bionor Immuno As Monomeric and multimeric immunogenic peptides
EP4144368B1 (fr) 2011-01-26 2025-02-26 GlaxoSmithKline Biologicals S.A. Régime d'immunisation contre le vrs
CN103842374A (zh) 2011-05-13 2014-06-04 诺华股份有限公司 融合前的rsv f抗原
MX2014014683A (es) 2012-06-06 2015-02-24 Bionor Immuno As Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
JP2022513001A (ja) 2018-11-13 2022-02-07 ヴァリエーション バイオテクノロジーズ インコーポレイテッド Ｂ型肝炎の治療のための免疫原性組成物
EP4103587A1 (fr) 2020-02-14 2022-12-21 Immunor AS Vaccin contre le coronavirus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584866D1 (de) * 1984-09-12 1992-01-23 Chiron Corp Hybridpartikel-immunogene.
BR8807310A (pt) * 1987-11-18 1990-03-13 Chiron Corp Polinucleotidio,polinucleotidio recombinante,vetor recombinante,celula hospedeira,sistema de expressao recombinante,celula transformada,polipeptidio,hcv,preparacao de polipeptidio,polipeptidio de hcv,polipeptidio purificado,polipeptidio recombinante,polipeptidio de fusao,anticorpo monoclonal,preparacao purificada de anticorpos policlonais,particula,sonda de polinucleotidio,kit anticorpo para epetopo de hcv,metodo para producao de polipeptidio,metodo para deteccao de acidos nucleicos de hcv,imunoensaio para detectar antigeno de hcv,imunoensaio para detectar anticorpos dirigidos contra antigeno de hcv,vacina para tratamento de infeccao de hcv,celula,celula infectada com hcv,metodo para producao de anticorpos para hcv e metodo para isolar cdna derivado do genoma de um agente infeccioso nao identificado
AU3748489A (en) * 1988-06-17 1990-01-12 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0414374B1 (fr) * 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Antigènes ainsi que les méthodes pour leur préparation
JP3156200B2 (ja) * 1989-09-15 2001-04-16 国立予防衛生研究所長 新規のｈｃｖ分離株
SU1678373A1 (ru) * 1989-10-18 1991-09-23 Киевский Научно-Исследовательский Институт Эпидемиологии И Инфекционных Болезней Им.Л.В.Громашевского Способ иммунокоррекции при зат жных формах гепатита
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
WO1992011291A1 (fr) * 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) VACCINS A BASE DE l'ANTIGENE D'ENVELOPPE DU VIRUS DE L'HEPATITE B

Also Published As

Publication number Publication date
EP0633784B2 (fr) 2001-10-17
ATE146678T1 (de) 1997-01-15
SA93130573B1 (ar) 2004-08-31
CA2132833C (fr) 2007-03-06
NO943571D0 (no) 1994-09-26
IL105161A0 (en) 1993-07-08
UA44688C2 (uk) 2002-03-15
DE69306940T3 (de) 2002-09-19
SG48375A1 (en) 1998-04-17
HU221253B1 (en) 2002-09-28
DE69306940D1 (de) 1997-02-06
AU1000802A (en) 2002-02-21
SI9300149B (sl) 2003-02-28
JP3470719B2 (ja) 2003-11-25
AP9300502A0 (en) 1993-04-30
RU94042386A (ru) 1996-08-20
NO309458B1 (no) 2001-02-05
JPH07505372A (ja) 1995-06-15
CZ283424B6 (cs) 1998-04-15
CZ235594A3 (en) 1995-02-15
DE69306940T2 (de) 1997-06-26
NZ249868A (en) 1997-03-24
ES2098029T5 (es) 2002-03-16
FI944442L (fi) 1994-09-26
EP0633784B1 (fr) 1996-12-27
AU767755B2 (en) 2003-11-20
RU2121849C1 (ru) 1998-11-20
FI110843B (fi) 2003-04-15
CN1072963C (zh) 2001-10-17
DK0633784T3 (da) 1997-01-20
CA2132833A1 (fr) 1993-10-14
KR100270134B1 (ko) 2000-10-16
CN1085805A (zh) 1994-04-27
ES2098029T3 (es) 1997-04-16
SI9300149A (en) 1993-12-31
GR3022174T3 (en) 1997-03-31
EP0633784A1 (fr) 1995-01-18
SK115294A3 (en) 1995-06-07
AU3751693A (en) 1993-11-08
HUT69931A (en) 1995-09-28
AU3397499A (en) 1999-08-19
MY111880A (en) 2001-02-28
AP570A (en) 1996-11-29
AU6445796A (en) 1996-11-07
FI944442A0 (fi) 1994-09-26
IL105161A (en) 1998-08-16
HK1003218A1 (en) 1998-10-16
DK0633784T4 (da) 2001-12-31
NO943571L (no) 1994-11-14
SK280160B6 (sk) 1999-09-10
HU9402758D0 (en) 1994-12-28
WO1993019780A1 (fr) 1993-10-14
KR950700757A (ko) 1995-02-20

Similar Documents

Publication Publication Date Title
MA23850A1 (fr) Procede de preparation de compositions vaccinantes
MA23918A1 (fr) Procede de preparation de compositions vaccinantes
MA23814A1 (fr) Procede de preparation de compositions vaccinantes
MA22894A1 (fr) Procede de preparation d'un vaccin.
MA23143A1 (fr) Procede pour la preparation de compositions vaccinantes .
MA23395A1 (fr) Procede de preparation de nouvelles formulations
FI914174A7 (fi) Menetelmä piperidyylialkyyliamiinien valmistamiseksi
MA22471A1 (fr) Procede de production de vaccin
MA24291A1 (fr) Procede pour la preparation de compositions de vaccin
MA23118A1 (fr) Procede pour la preparation de compositions de vaccins contre la grippe .
MA21977A1 (fr) Procede de preparation de compositions bitumineuses .
FR2722210B1 (fr) Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
IS3814A (is) Aðferð til framleiðslu á lyfjablöndum
FR2664274B1 (fr) Procede de preparation de sulfates cycliques.
MA23663A1 (fr) Procede de preparation de formulations pharmaceutiques
ITMI931680A1 (it) Procedimento per la preparazione di alcansolfonammidi
MA21854A1 (fr) Procede de preparation de phosphonomethyl thioethoxypurines .
FI933755A7 (fi) Menetelmä trans-piperidiini-2,5-dikarboksylaattien valmistamiseksi
FR2695645B1 (fr) Procédé de préparation de polyaminoborazines.
FI913464A7 (fi) Menetelmä 1-hydroksimetyylipyratsolien valmistamiseksi
IT9067657A1 (it) Procedimento per la preparazione di alfa-alchil-lattoni.
FI922125A7 (fi) Mikrobiologinen menetelmä 5-hydroksipyratsiinikarboksyylihapon valmistamiseksi
FI923866A7 (fi) Menetelmä 1-hydroksialkyyli-5-nitroimidatsolien valmistamiseksi
FI930237A7 (fi) Menetelmä 4,6-dialkoksipyrimidiinien valmistamiseksi
FI940338L (fi) Menetelmä 13alfa-sinnamoyylibakkatiini III:n tai -10-desasetyylibakkatiini III:n valmistamiseksi